This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
Genomic Biomarker Testing
PEACE-3 Trial
PROfound Trial
PSMAfore Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
PSMAddition Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
BOND-003 Cohort P
CORE-001 Study
CORE-008
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Daniel D. Joyce, MD, MS
Bladder Cancer
Non-Muscle Invasive Bladder Cancer
Ashish Kamat, MD
Muscle-Invasive Bladder Cancer
Advanced & Metastatic Bladder Cancer (mUC)
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher® Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
mCRPC with Bone Metastasis
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
Testicular, Penile & Rare GU Malignances
Testicular Cancer
Functional Urology
Functional Urology
Alan J. Wein, MD, PhD (hon.)
Urologic Catheters - CAUTI Challenges
Videos
Exclusives
Conferences
Disparities: Social Determinants of Health
Exclusive Collaborations
Health Policy in Urological Diseases
Independent Medical Education
Journal Clubs
Practice Guidelines Reviews
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Functional Urology
Men's Health
Pelvic Health
Actionable Clinical Data
Bladder Cancer
NMIBC with CIS: Evidence, Practice & Emerging Research
Risk-Stratified NMIBC Management
Trials in Progress
Prostate Cancer
Localized Prostate Cancer
CLARIFY
ESCAPE
FORT
NRG-GU 0101
RTIRE
High Risk BCR HSPC
ARASTEP
Oligometastatic Prostate Cancer
METANOVA
mHSPC
ARASEC
ASPIRE
MEVPRO-3
mCRPC
ECLIPSE
LEGION-100
MEVPRO-1 & 2
PROMISE
SECuRE
Bladder Cancer
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SNMMI 2026
ASCO 2026
AUA 2026
APCCC 2026
PSMA and Beyond 2026
All Conferences
View All
PCF
UroAlert - GU Oncology Daily
June 22, 2026
Videos
Peer-to-Peer Clinical Conversations
ECLIPSE Trial Explores Dosimetry for PSMA-Targeted Therapy in mCRPC - Frankis Almaguel & Jason Hafron
Jason Hafron
Frankis Almaguel presents ECLIPSE trial dosimetry data from 26 metastatic castration-resistant prostate cancer patients using multi-point SPECT CT.
View
Cost-Effectiveness of Bladder Cancer Treatments Varies by Patient Scenario and Preference - Amanda Myers
Amanda Myers
Amanda Myers discusses a cost-effectiveness analysis of treatments for BCG-unresponsive carcinoma in situ.
View
Beyond the Abstracts
Development of the PREDICT-Kidney Online Tool to Promote Informed Decision-Making About Kidney Cancer Follow-up Care: A Qualitative Co-Design Study - Beyond the Abstract
Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists - Beyond the Abstract
Conference Coverage
ASCO 2026: Phase 2 Multicenter Trial of Chemoimmunotherapy for Patients with Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP)
ASCO 2026: Early Results of COMPPARE, a Prospective Comparison of Outcomes with Proton and Photon Radiation in Prostate Cancer
ASCO 2026: Durvalumab Monotherapy Versus Active Monitoring for Resected Primary RCC in RAMPART: An International, Phase 3, Randomized Controlled Trial
AUA 2026: SUO-CTC: Bladder Trials Update
AUA 2026: Perioperative and Oncologic Outcomes of Consolidative Surgery for Advanced Urothelial Carcinoma Following Induction Enfortumab Vedotin and Pembrolizumab: A Multicenter Experience
Articles
Editor Selected Abstracts and Commentaries
Bladder Cancer
Characteristics of Patients With Advanced or Metastatic Urothelial Cancer Unable to Complete Six Cycles Chemotherapy.
Clinical and pathological predictors of early recurrence after neoadjuvant cisplatin gemcitabine in muscle invasive bladder cancer in the RealBLADDER study.
Comprehensive genome-wide association study into multiple recurrence and progression risk in non-muscle invasive bladder cancer.
Penile & Urethral Cancers
A focused systematic review and meta-analysis of robot-assisted inguinal lymphadenectomy versus open inguinal lymph node dissection in penile cancer.
Renal Cancer
Percutaneous Cryoablation for Small Renal Masses in a High-Risk Cohort: Oncologic and Functional Outcomes from a Five-Year Single-Center Experience.
Lineage infidelity in FH-deficient RCC with secondary somatic alterations: a case report and implications for diagnosis and treatment.
Geospatial correlation of industrial plastics emissions with bladder and kidney cancer burden in Ohio.
Prostate Cancer
Mortality in Castration Resistant Prostate Cancer Patients With and Without Pre-Existing Cardiovascular Disease Receiving Oral Androgen Receptor Pathway Inhibitors.
Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer.
Prostate Cancer Working Group 4 Recap.
Association of asymptomatic PSA testing on prostate cancer mortality; a case control study in general practice.
Standardizing PSMA PET/CT reporting in prostate cancer: from structured frameworks to AI-assisted interpretation.
Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib.
Long-term Outcomes in Men with Stable PSA During 5-α Reductase Inhibitor Therapy After Negative Prostate Biopsy: Population-based Study.
Upper Tract Tumors
Clinicopathological Predictors of Survival After Radical Nephroureterectomy for UTUC: A Propensity Score-Matched Multicenter Analysis.
CONNECT WITH US
Questions or Comments? Email us at
editors@urotoday.com
Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523
You are receiving this email because you have chosen to receive emails from UroToday.
Add us to your address book
View this email as a web page
Forward to a colleague
Manage your subscriptions
Unsubscribe
Copyright ©2026 Digital Science Press, LLC
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free